Cancer diagnostics using biomarkers
Disclosed herein, in certain instances, are methods, systems and kits for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods, systems and kits for determining the treatment modality of a cancer in a subject. The methods, systems and kits comprise expression-based analysis of biomarkers. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.
1. A method comprising:
(a) obtaining or having obtained an expression level of a plurality of targets in a sample obtained from a subject with prostate cancer, wherein the plurality of targets comprises ten or more target nucleic acid sequences selected from NFIB, NUSAP1, ZWILCH, ANO7, PCAT-32, UBE2C, CAMK2N1, MYBPC1, PBX1, THBS2, EPPK1, IQGAP3, LASP1, PCDH7, RABGAP1, GLYATL1P4, S1PR4, TNFRSF19 and TSBP, and wherein the plurality of targets comprises at least one target nucleic acid sequence selected from NFIB, ZWILCH, PCAT-32, EPPK1, IQGAP3, LASP1, PCDH7, RABGAP1, GLYATL1P4, S1PR4, TNFRSF19 and TSBP;
(b) prognosing the subject as later developing metastatic cancer based on at least the expression level of each of the plurality of targets in the sample obtained in step (a), and
(c) administering a cancer treatment to the subject prognosed as later developing metastatic cancer in step (b), wherein the cancer treatment is a chemotherapeutic agent or radiation treatment.
2. The method of claim 1 , wherein the plurality of targets comprises a coding target.
3. The method of claim 2 , wherein the coding target is an exonic sequence.
4. The method of claim 1 , wherein the plurality of targets comprises a non-coding target.
5. The method of claim 4 , wherein the non-coding target comprises an intronic sequence or partially overlaps an intronic sequence.
6. The method of claim 4 , wherein the non-coding target comprises a sequence within the UTR or partially overlaps with a UTR sequence.
7. The method of claim 1 , wherein the nucleic acid sequence is a DNA sequence.
8. The method of claim 1 , wherein the nucleic acid sequence is an RNA sequence.
9. The method of claim 1 , wherein the plurality of targets comprises NFIB, NUSAP1, ZWILCH, ANO7, PCAT-32, UBE2C, CAMK2N1, MYBPC1, PBX1, THBS2, EPPK1, IQGAP3, LASP1, PCDH7, RABGAP1, GLYATL1P4, S1PR4, TNFRSF19 and TSBP.
10. The method of claim 1 , wherein the plurality of targets comprises SEQ ID NOs: 1-22.
11. The method of claim 1 , wherein the plurality of targets comprises SEQ ID NOs: 1-43.
12. The method of claim 1 , further comprising sequencing the plurality of targets.
13. The method of claim 1 , further comprising hybridizing the plurality of targets to a solid support.
14. The method of claim 13 , wherein the solid support is a bead or array.